Menu
GeneBe

5-1216947-T-G

Variant summary

Our verdict is Pathogenic. Variant got 22 ACMG points: 22P and 0B. PVS1PM2PP3_StrongPP5_Very_Strong

The NM_001003841.3(SLC6A19):c.1173+2T>G variant causes a splice donor change. The variant allele was found at a frequency of 0.000267 in 1,612,406 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).

Frequency

Genomes: 𝑓 0.00024 ( 0 hom., cov: 35)
Exomes 𝑓: 0.00027 ( 0 hom. )

Consequence

SLC6A19
NM_001003841.3 splice_donor

Scores

2
2
3
Splicing: ADA: 1.000
2

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:10

Conservation

PhyloP100: 5.46
Variant links:
Genes affected
SLC6A19 (HGNC:27960): (solute carrier family 6 member 19) This gene encodes a system B(0) transmembrane protein that actively transports most neutral amino acids across the apical membrane of epithelial cells. Mutations in this gene may result in Hartnup disorder, an inherited disease with symptoms such as pellagra, cerebellar ataxia, and psychosis. The expression and function of B0AT1 (SLC6A19) in intestinal cells depends on the presence of the accessory protein angiotensin-converting enzyme 2 (ACE2) which, among other functions, acts as a chaperone for membrane trafficking of B0AT1. The ACE2 is also the cellular receptor for severe acute respiratory syndrome-coronavirus (SARS-CoV) and for SARS-CoV-2 that is causing the coronavirus 2019 (COVID-19) pandemic [provided by RefSeq, Jul 2020]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 22 ACMG points.

PVS1
Splicing variant, LoF is a know mechanism of disease, No cryptic splice site detected. Exon removal results in frameshift change.
PM2
Very rare variant in population databases, with high coverage;
PP3
Splicing scoreres supports a deletorius effect: Scorers claiming Pathogenic: dbscSNV1_ADA, dbscSNV1_RF, max_spliceai. No scorers claiming Uncertain. No scorers claiming Benign.
PP5
Variant 5-1216947-T-G is Pathogenic according to our data. Variant chr5-1216947-T-G is described in ClinVar as [Pathogenic]. Clinvar id is 449553.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr5-1216947-T-G is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
SLC6A19NM_001003841.3 linkuse as main transcriptc.1173+2T>G splice_donor_variant ENST00000304460.11

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
SLC6A19ENST00000304460.11 linkuse as main transcriptc.1173+2T>G splice_donor_variant 1 NM_001003841.3 P1
SLC6A19ENST00000515652.5 linkuse as main transcriptc.*118+2T>G splice_donor_variant, NMD_transcript_variant 2

Frequencies

GnomAD3 genomes
AF:
0.000237
AC:
36
AN:
152218
Hom.:
0
Cov.:
35
show subpopulations
Gnomad AFR
AF:
0.0000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000654
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00141
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000265
Gnomad OTH
AF:
0.000478
GnomAD3 exomes
AF:
0.000296
AC:
74
AN:
249668
Hom.:
0
AF XY:
0.000303
AC XY:
41
AN XY:
135256
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000557
Gnomad NFE exome
AF:
0.000535
Gnomad OTH exome
AF:
0.000327
GnomAD4 exome
AF:
0.000271
AC:
395
AN:
1460188
Hom.:
0
Cov.:
36
AF XY:
0.000270
AC XY:
196
AN XY:
726400
show subpopulations
Gnomad4 AFR exome
AF:
0.0000299
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.000760
Gnomad4 NFE exome
AF:
0.000305
Gnomad4 OTH exome
AF:
0.000232
GnomAD4 genome
AF:
0.000237
AC:
36
AN:
152218
Hom.:
0
Cov.:
35
AF XY:
0.000323
AC XY:
24
AN XY:
74366
show subpopulations
Gnomad4 AFR
AF:
0.0000241
Gnomad4 AMR
AF:
0.0000654
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00141
Gnomad4 NFE
AF:
0.000265
Gnomad4 OTH
AF:
0.000478
Alfa
AF:
0.000153
Hom.:
0
Bravo
AF:
0.000102
ESP6500AA
AF:
0.000227
AC:
1
ESP6500EA
AF:
0.000233
AC:
2
ExAC
AF:
0.000461
AC:
56
EpiCase
AF:
0.000164
EpiControl
AF:
0.000356

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:5
Pathogenic, no assertion criteria providedclinical testingGenome Diagnostics Laboratory, University Medical Center Utrecht-- -
Pathogenic, criteria provided, single submitterclinical testingGeneDxDec 04, 2019Canonical splice site variant in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 25525159, 15286788, 25082825, 15286787, 31589614, 33144682) -
Pathogenic, no assertion criteria providedclinical testingDiagnostic Laboratory, Department of Genetics, University Medical Center Groningen-- -
Pathogenic, criteria provided, single submitterclinical testingInvitaeNov 24, 2023This sequence change affects a donor splice site in intron 8 of the SLC6A19 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SLC6A19 are known to be pathogenic (PMID: 15286787, 15286788). This variant is present in population databases (rs142979576, gnomAD 0.07%). Disruption of this splice site has been observed in individuals with Hartnup disorder (PMID: 15286787, 15286788). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 449553). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, no assertion criteria providedclinical testingClinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center-- -
Neutral 1 amino acid transport defect Pathogenic:3
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpApr 14, 2023Variant summary: SLC6A19 c.1173+2T>G is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes the canonical 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0003 in 249668 control chromosomes. This frequency does not allow conclusions about variant significance. c.1173+2T>G has been reported in the literature as a homozygous or compound heterozygous genotype in multiple individuals affected with Hartnup Disease (example, Kleta_2004, Azamov_2008). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityDec 01, 2021- -
Pathogenic, no assertion criteria providedliterature onlyOMIMSep 01, 2004- -
SLC6A19-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact SciencesJan 05, 2024The SLC6A19 c.1173+2T>G variant is predicted to disrupt the GT donor site and interfere with normal splicing. This variant has been reported in the compound heterozygous and homozygous states in multiple individuals with Hartnup disorder (Table 1, Seow et al. 2004. PubMed ID: 15286788; Kleta et al. 2004. PubMed ID: 15286787). This variant is reported in 0.068% of alleles in individuals of European (Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/5-1217062-T-G). Variants that disrupt the consensus splice donor site in SLC6A19 are expected to be pathogenic. This variant is interpreted as pathogenic. -
Neutral 1 amino acid transport defect;C0268654:Iminoglycinuria;C0543541:Hyperglycinuria Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsMay 09, 2022- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
0.36
D
BayesDel_noAF
Benign
-0.18
Cadd
Uncertain
25
Dann
Benign
0.93
Eigen
Uncertain
0.61
Eigen_PC
Uncertain
0.33
FATHMM_MKL
Pathogenic
0.97
D
MutationTaster
Benign
1.0
D
GERP RS
3.7

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
1.0
dbscSNV1_RF
Pathogenic
0.89
SpliceAI score (max)
0.98
Details are displayed if max score is > 0.2
DS_DG_spliceai
0.23
Position offset: 2
DS_DL_spliceai
0.98
Position offset: -2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs142979576; hg19: chr5-1217062; API